Protein Fragments: From Biomarkers to Therapeutic Targets—A Focus on α1‐Antitrypsin‐Derived Peptides
Mediators of Inflammation · 2026
DOI: 10.1155/mi/6516930 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mediators of Inflammation, 2026. Verfasst von Friedemann Börner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, Jena, Germany, uniklinikum-jena.de. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin, Biomarkers, Peptides, Peptide Fragments. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Centre of Lung Research, Projekt DEAL.
Abstract (Originalsprache)
Protein fragments are increasingly recognized as both biomarkers and therapeutic targets, offering important insights into disease mechanisms and potential intervention strategies. Evidence from in vitro and in vivo studies indicates that these fragments are not merely degradation products but possess distinct biological activities, actively modulating immune signaling and contributing to both acute and chronic inflammatory processes. Here, we provide an overview of proteases and their inhibitors, with a particular focus on peptide fragments generated through proteolytic cleavage. Special emphasis is placed on fragments derived from α1‐antitrypsin (AAT), an acute‐phase glycoprotein and major inhibitor of neutrophil elastase and other serine proteases. AAT‐derived peptides of varying lengths, generated by both target and nontarget proteases, including metalloproteases, have been detected in human biological fluids and tissues. Beyond reflecting proteolytic activity, these peptides provide clinically relevant information on disease‐associated inflammation and tissue remodeling. Accordingly, they are emerging as promising diagnostic, monitoring, and predictive biomarkers. Here, we summarize current knowledge on cleaved AAT fragments, their biological functions, and their potential clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, Jena, Germany, uniklinikum-jena.de.
- Department of Biochemistry and Medical Genetics, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland, sum.edu.pl.
- Department of Respiratory Medicine, Member of the German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Hannover Medical School, Hannover, Germany, mh-han…
- Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
ORCID-Profile: Friedemann Börner, Aleksandra Jezela-Stanek, Sabina Janciauskiene
Förderung
- German Centre of Lung Research
- Projekt DEAL
Zitieren
APA
Börner, F., Iwanicki, T., Held, J., Chorostowska-Wynimko, J., Jezela-Stanek, A., & Janciauskiene, S. (2026). Protein Fragments: From Biomarkers to Therapeutic Targets—A Focus on α1‐Antitrypsin‐Derived Peptides. Mediators of Inflammation. https://doi.org/10.1155/mi/6516930
Vancouver
Börner F, Iwanicki T, Held J, Chorostowska-Wynimko J, Jezela-Stanek A, Janciauskiene S. Protein Fragments: From Biomarkers to Therapeutic Targets—A Focus on α1‐Antitrypsin‐Derived Peptides. Mediators of Inflammation. 2026. doi:10.1155/mi/6516930
BibTeX
@article{Brner2026,
author = {Börner, Friedemann and Iwanicki, Tomasz and Held, Julia and Chorostowska-Wynimko, Joanna and Jezela-Stanek, Aleksandra and Janciauskiene, Sabina},
title = {Protein Fragments: From Biomarkers to Therapeutic Targets—A Focus on α1‐Antitrypsin‐Derived Peptides},
journal = {Mediators of Inflammation},
year = {2026},
doi = {10.1155/mi/6516930}
}
EUVIMED